AstraZeneca
growth from covid medicines stable total revenue reiterating guidance growth in oncology i and rare disease offset decline in covid medicines total revenue stable core reiterating guidance core to increase by a high single digit to low double digit | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
April 2023
Slide
5 of 41
Related slides by other companies
Samsara
Investor Presentation
August 2022
financial guidance non | Samsara
Samsara
Investor Presentation
December 2022
financial guidance non | Samsara
Markforged
Results
March 2024
financial guidance revenue non gross margin non operating loss non million million | Markforged
Blend
Investor Day
February 2024
updated guidance | Blend
Other recent decks by AstraZeneca
See all presentations (27 decks)
Results
February 2024
Investor Conference
January 2024
Results
November 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io